Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Rituximab 7Pyridostigmine Bromide 5Prednisone 5efgartigimod alfa 4Hizentra 4telitacicept 3Immunoglobulins, Intravenous 3Cyclophosphamide 3Azathioprine 3thymoglobulin 2fludarabine 2Thymectomy 2Steroids 2Mycophenolic Acid 2Data Collection 2Blood Specimen Collection 2zilucoplan 1tofacitinib 1tocilizumab 1talquetamab 1sargramostim 1rozanolixizumab 1prednylidene 1gamma-Globulins 1deltacortene 1carmustine, poliferprosan 20 drug combination 1bu-zhong-yi-qi-tang 1apraclonidine 1Walk Test 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myasthenia Gravis × apraclonidine × Clear all
NCT05045248 2021-09-16

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

American University of Beirut Medical Center

Phase 2 Completed
10 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡